A 68-year-old man with a history of hypertension and diabetes mellitus presents to the emergency department with acute onset chest pain and dyspnea. His ECG shows ST-segment elevation in leads II, III, and aVF. Troponin I is elevated at 2.8 ng/mL. He is immediately taken for primary percutaneous coronary intervention (PCI). During the procedure, a drug-eluting stent is placed in the right coronary artery. The interventional cardiologist prescribes dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. After 6 months, the patient develops recurrent angina. Coronary angiography reveals in-stent restenosis. The cardiologist switches clopidogrel to ticagrelor. Which of the following best explains the rationale for switching to ticagrelor in this patient?

Question

Accepted Answer

D. Ticagrelor has a faster onset of action and achieves higher platelet inhibition compared to clopidogrel, reducing the risk of stent thrombosis. ## Rationale for Switching to Ticagrelor

**Key Point:** Ticagrelor is a cyclopentyltriazoloprimidine (not a thienopyridine) that acts as a direct, reversible P2Y12 inhibitor, achieving faster and more potent platelet inhibition than clopidogrel.

### Mechanism of Action Comparison

| Feature | Clopidogrel | Ticagrelor |
|---------|------------|----------|
| Drug class | Thienopyridine (prodrug) | Cyclopentyltriazoloprimidine (active) |
| Activation | Requires hepatic metabolism (CYP3A4, CYP2C19) | Direct P2Y12 inhibitor; no prodrug activation |
| Onset of action | 3–5 days (loading dose: 24 hrs) | 30 minutes (loading dose: 2 hrs) |
| Platelet inhibition | ~50% at therapeutic dose | ~70–80% at therapeutic dose |
| Reversibility | Irreversible | Reversible |
| Elimination | Hepatic metabolism | Hepatic metabolism + renal clearance |

**High-Yield:** In patients with in-stent restenosis or recurrent ischemic events on clopidogrel, switching to ticagrelor provides superior platelet inhibition and faster onset, reducing the risk of acute stent thrombosis and recurrent coronary events.

**Clinical Pearl:** Ticagrelor is particularly beneficial in patients with:
  - Acute coronary syndromes (ACS) — shown to reduce mortality in PLATO trial
  - Clopidogrel resistance or poor response
  - Recurrent ischemic events despite DAPT with clopidogrel
  - CYP2C19 loss-of-function polymorphisms (which impair clopidogrel activation)

### Why Ticagrelor Over Clopidogrel?

1. **Faster onset:** Achieves therapeutic platelet inhibition within 2 hours vs. 24 hours for clopidogrel loading dose.
2. **Greater potency:** Achieves 70–80% platelet inhibition vs. ~50% with clopidogrel.
3. **Reversible binding:** Allows faster platelet recovery if urgent surgery is needed.
4. **No prodrug metabolism:** Not dependent on CYP2C19 activation; avoids genetic polymorphism-related resistance.

**Warning:** Do not confuse ticagrelor with prasugrel (another P2Y12 inhibitor). Prasugrel is also a thienopyridine prodrug but has a faster onset than clopidogrel; however, ticagrelor is preferred in ACS due to superior outcomes in the PLATO trial and reversible mechanism.

### Dosing

- **Loading dose:** 180 mg
- **Maintenance dose:** 60 mg twice daily (or 90 mg twice daily in some high-risk settings)
- **Duration:** Typically 12 months with aspirin for ACS with stent placement

Answer

A. Ticagrelor has a longer half-life and can be dosed once daily, improving patient compliance

Answer

B. Ticagrelor is a thienopyridine derivative with superior bioavailability and does not require hepatic metabolism

Answer

C. Ticagrelor is indicated specifically for in-stent restenosis and prevents neointimal hyperplasia

Explanation

Practice similar questions